Background: Management of Mucormycosis presents a greater challenge compared to COVID-19. The primary aim of this study is to elucidate the demographic characteristics, clinical manifestations, and potential risk factors associated with COVID-19-related Mucormycosis. Methods: This retrospective hospital based cross-sectional study encompassed a cohort of 43 patients. The inclusion criteria involved individuals diagnosed with Mucormycosis who had a documented history of COVID 19 infection confirmed through either Reverse Transcription Polymerase Chain Reaction (RT-PCR) or Rapid Antigen testing. Patients with prior episodes of Mucormycosis or those not admitted to a hospital were excluded from the study. Results: The study comprised 63.45% male and 36.55% female patients, with an average age of 51.2 ± 9.7 years. A substantial proportion of the patients were engaged in agricultural activities. The predominant sites of sinus involvement were Maxillary, followed by Ethmoid and Sphenoid sinuses. Notably, 21.22% of the patients had a pre-existing diabetic condition, while 62.78% presented uncontrolled blood glucose levels. Additionally, 27.11% had a known history of hypertension. During their management of acute COVID infection, 68.35% received steroid treatment, 53.95% necessitated oxygen therapy, 31.11% required Critical Care Unit (CCU) admission, and 5.5% relied on ventilator support. Conclusion: Male individuals exhibit a higher susceptibility to post-COVID-19 Mucormycosis compared to females. Furthermore, individuals involved in farming-related activities face an elevated risk of contracting the infection. Key contributory factors to the increased occurrence of post-COVID Mucormycosis encompass the overuse of steroids, poorly managed blood sugar levels, prolonged hospitalization, and the requirement for ICU and ventilator interventions during the course of COVID infection.